Chortoglyphus arcuatus allergen (Chor a)

Chortoglyphus arcuatus allergens are a group of proteins derived from the storage mite Chortoglyphus arcuatus, which is a common inhabitant of agricultural environments such as granaries and barns (WHO/IUIS Allergen Nomenclature, 2024). These allergens, most notably Chor a 1 and Chor a 2, are significant triggers for Type I hypersensitivity reactions in sensitized individuals, particularly those with occupational exposure like farmers and bakers (Armentia et al., 1994, PubMed). Clinically, exposure to these allergens leads to conditions such as allergic rhinitis, bronchial asthma, and conjunctivitis through the cross-linking of IgE on mast cells and basophils (Vidal et al., 2004, PubMed). Biologically, these proteins often serve as enzymes, such as cysteine proteases, or transport proteins within the mite's physiology (UniProt, 2024). In the pharmaceutical industry, these allergens are the primary components of diagnostic extracts and allergen-specific immunotherapy (AIT) products. AIT aims to modify the underlying disease by inducing long-term immune tolerance, thereby reducing symptoms and preventing the progression of allergic disease. The treatment involves the gradual administration of the allergen to shift the immune response from a Th2-dominated profile to a regulatory T-cell response. Understanding the molecular structure and cross-reactivity of these allergens is crucial for developing effective standardized treatments for storage mite-induced allergies.

Other names

Storage mite allergensBarn mite allergensGrain mite allergensChortoglyphus arcuatus mite allergens

Allergen immunotherapy (AIT) works by inducing peripheral T-cell tolerance, increasing the production of protective antibodies such as IgG4, and shifting the immune response from a Th2-dominated profile to a Th1 or regulatory T-cell (Treg) profile (PubMed, 2024).